Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
clinical deteriorationclinical improvementdeathsviral clearance
A EFFACER BBV152 (Bharat Biotech, India)0----
A EFFACER Janssen Ad.26.COV2.S vaccine (JNJ-78436725)0----
A EFFACER_ Vero cell0----
A EFFACER_sequential Immunization0----
BCG vaccination0----
complete primary vaccine series0----
CoVLP (MT-2766, Medicago)0----
DNA vaccine0----
ebola vaccine0----
first booster dose0----
heterologous prime-boost0----
Inactivated virus vaccine0----
mRNA vaccine0----
Non replicating viral vector0----
protein subunit vaccine0----
Replicating Viral Vector0----
seasonal influenza vaccines0----
second booster dose0----
virus-like particles vaccine0----